A prospective trial of short‐fractionation radiotherapy for the palliation of liver metastases

The purpose of this study was to prospectively examine the effectiveness and tolerability of a simple radiotherapy technique for the palliation of symptomatic liver metastases. Twenty‐eight patients with symptomatic liver metastases were enrolled from seven centres, and received targeted (partial or whole) liver irradiation consisting of 10 Gy in two fractions over 2 days. Symptoms at baseline were hepatic pain (27 patients), abdominal distension (19), night sweats (12), nausea (18) and vomiting (eight). Twenty‐two patients (76%) had failed previous treatment with chemotherapy, hormonal therapy and/or high‐dose steroids. Symptoms and potential toxicities were prospectively assessed at the time of treatment, then 2, 6 and 10 weeks later. Individual symptom response rates were 53?66% at 2 weeks. Partial or complete global symptomatic responses were noted in 15 patients (54%) overall. The treatment was well tolerated with two patients (7%) experiencing grade 3 toxicity (one vomiting and one diarrhoea); however, four patients reported temporary worsening of pain shortly after treatment. This simple and well‐tolerated treatment achieves useful palliation.     

Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).

BACKGROUND: The purpose of this study was to evaluate the tolerance and efficacy of combining i.v. irinotecan, 5-fluorouracil (5-FU) and leucovorin (LV) with hepatic arterial infusion (HAI) of pirarubicin in non-resectable liver metastases from colorectal cancer. PATIENTS AND METHODS: Thirty-one patients were included in a phase II trial with i.v. irinotecan/5-FU/LV administered every 2 weeks, combined with HAI pirarubicin 60 mg/m(2) on day 1 every 4 weeks. In most cases HAI was administered via a percutaneous catheter. RESULTS: The main grade 3/4 toxicity was neutropenia, encountered in 78% of the patients. When all patients were considered in the analysis, tumour response rate was 15 out of 31 [48%; 95% confidence interval (CI) 32% to 65%]. Liver resection was made possible in 11 patients (35%; 95% CI 21% to 53%). There were no toxic death. Median overall survival was 20.5 months, and median progression-free survival was 9.1 months. In patients with completely resected metastases, median overall survival was not reached and median progression-free survival was 20.2 months. CONCLUSION: The multimodality approach used in the present study was well-tolerated and yielded dramatic responses. An aggressive approach combining i.v. and HAI chemotherapy deserves further investigation.     

乳腺癌肝转移的介入治疗

[目的]观察乳腺癌肝转移肝动脉化疗栓塞（TACE）的疗效。[方法]对38例经检查证实的乳腺癌肝转移患者TACE治疗。[结果]TACE治疗完全缓解（CR）2例，部分缓解（PR）12例，稳定（SD）19例，进展（PD）5例，总有效率为36、8%（14/38）。TACE治疗1、2、3年生存率分别为59%、32%、21%。[结论]TACE治疗乳腺癌肝转移治疗有一定疗效，值得提倡。     

应用冷循环集束电极射频治疗晚期肝癌的疗效观察

[目的]观察冷循环集束电极射频治疗晚期肝癌的效果。[方法]冷循环集束电极射频治疗38例晚期肝癌，术后每月复查CT观察病变区液化坏死和病灶缩小情况以及增强扫描是否强化、患者生存质量及AFP变化。[结果]术后1个月CT显示全部病灶均出现部分液化坏死及CT扫描不强化，3个月后CT扫描5例患者肿瘤完全坏死。其余大部分坏死。全部患者术后1个月KPS评分均提高10分以上。随访AFP变化与肿瘤毁损情况一致。术后CT复查病灶液化坏死范围大或病灶缩小明显的病例AFP下降显著。[结论]冷循环集束电极射频治疗是一种安全、有效、耐受性好的晚期肝癌治疗技术。初步结果显示该治疗能够提高患者生存质量、延长生存期，值得深入研究并推广。     

鲨肝活性肽的免疫调节和抗细胞凋亡作用

目的　为了选择鲨肝活性肽 (SHAP)临床应用的适应症并了解其作用机制。方法　分离培养人外周血单核细胞 (PBMC) ,检测SHAP对其分泌IFN α和IFN γ的影响 ;用环磷酰胺 (Cy)建立免疫低下模型 ,检测SHAP对免疫低下小鼠血清溶血素的生成及血清IL 2水平的影响 ;用流式细胞仪分析SHAP对对乙酰氨基酚 (AAP)诱导小鼠肝损伤模型中细胞凋亡的影响 :用Fas单克隆抗体诱导小鼠暴发性肝炎和抑制肝癌细胞株SMMC772 1的增殖 ,用SHAP处理后 ,分析小鼠血清谷丙转氨酶 (GPT)的水平及SMMC772 1增殖的变化情况。结果　SHAP能够有效诱导PBMC分泌IFN α和IFN γ ,促进免疫低下小鼠血清溶血素的生成和提高血清IL 2的水平 ,显著降低AAP诱导的肝细胞凋亡。 5 0mg·L- 1的SHAP可消除 5mg·L- 1Fas单克隆抗体对SMMC772 1增殖的抑制作用。 3mg·kg- 1的SHAP能显著降低Fas单克隆抗体诱导的暴发性肝炎小鼠的血清GPT水平。结论　SHAP具有免疫调节作用和抗细胞凋亡的作用 ,可能是SHAP防治肝炎的作用机制之一。     

急性阑尾炎术前漏诊右半结肠癌14例分析

目的 探讨预防或减少急性阑尾炎术前漏诊右半结肠癌的措施及二者并存的术中处理。方法 对我院1990年1月～2002年10月收治的14例急性阑尾炎术前漏诊右半结肠癌的原因及并存机理进行回顾性分析。结果 14例漏诊患者中，5例行Ⅰ期右半结肠切除术；3例行Ⅰ期右半结肠切除、回肠造瘘术；2例行I期可疑病灶切除、回肠或盲肠造瘘术，Ⅱ期行右半结肠切除术；3例行回肠造瘘、腹腔引流术，Ⅱ期行右半结肠切除术；1例单纯行阑尾切除术，漏诊肝曲结肠癌，术后并发肠梗阻，剖腹控查行Ⅰ期右半结肠切除、回肠造瘘术。结论 掌握外科基本理论，遵循外科基本原则，避免惯性思维，减少漏诊机会，常能够避免急性阑尾炎术前漏诊右半结肠癌导致处理不当而带来的一系列问题。     

扁桃体周脓肿感染途径的探讨

为探讨扁桃体周脓肿的真正发病机理、感染途径，对连续诊治的１３１例扁周脓肿患者进行研究。其中８３例患侧的扁桃体被切除，切除之扁桃体外侧面均平整。通过８３例组织学观察，扁桃体上极表面既无扁桃溃破亦无脓瘘，邻接扁桃体上方之软腭粘膜下发现有感染及／或纤维化的小唾液腺（Ｗｅｂｅｒ腺），这些与扁桃体相邻的腺体在其他非扁周脓肿患者则显示正常形态与结构。从而认为扁桃体周围的化脓性感染可能与Ｗｅｂｅｒ腺有关，而非急性扁桃体炎。主张早期扁桃体切除术治疗扁周脓肿，目的在于获得充分引流。     

不同固定剂及固定时间对PCR扩增效果的影响

本研究选取五种不同固定液，分别按四种固定时间（12小时，24小时，48小时和72小时）对存在有HBVDNA的人肝癌组织进行固定，脱水包埋。然后提取组织DNA，观察不同固定液及固定时间对PCR扩增效果的影响。同时，还比较了从蜡块中制取PCR模板的四种方法。结果显示：新配中性缓冲甲醛液对组织DNA破坏较小，对PCR扩增效果影响亦较小且成本费用相对较低，固定时间最好不超过48小时。长期放置的用自来水配制的甲醛固定液对组织DNA破坏较大，DNA降解严重，直接影响PCR扩增效果。在用蜡块组织制备DNA模板上，传统酶消化，酚-氯仿抽提，酒精沉淀较为稳定，但所需组织相对较多。对小块组织，充分脱蜡，用双蒸水充分煮沸是制备PCR模板较简便的方法。根据本研究，笔者建议，在目前我国日常病理工作中，应重视对固定液的选择及固定时间的限制，以便能为进一步基因诊断提供先决条件。     

实验性脑脓肿影像学改变的病理基础研究

目的：明确不同时期动物脑脓肿的影像学特征及其相应的病理学改变。方法：制备脑脓肿狗动物模型１４只，采用ＣＴ、ＭＲＩ检查结合多项病理学观测进行动态分析。结果：脑炎期ＭＲＩ对炎症坏死区及水肿范围的显示较ＣＴ扫描更为清晰准确。包膜形成期：ＣＴ上脑脓肿包膜强化是炎症区血脑屏障破坏和新生血管形成所致；ＭＲＩＴ２加权成像上包膜的低信号“暗带”与包膜上的巨噬细胞堆积有关，延迟扫描和ＭＲＩ均能有效地区分脑脓肿的急性脑炎期和包膜形成期，但ＭＲＩ更加准确、迅速。结论：脑脓肿的ＭＲＩ特征与其临床分期及病理学变化的相关性较好，能更加准确、简便、迅速地区别脓肿的脑炎期和包膜形成期，可作为临床诊治脑脓肿的有力参考。     

疏肝理脾片抗大鼠免疫性肝纤维化研究

用牛血清白蛋白（ＢＳＡ）造成大鼠免疫损伤性肝纤维化模型，观察疏肝理脾片对肝纤维组织增生程度、肝羟脯氨酸（Ｈｙｐ）含量和血清透明质酸（ＨＡ）及肝功能的影响。结果表明疏肝理脾片能明显降低肝Ｈｙｐ含量，减轻肝纤维组织增生程度，并较好地提高血清白蛋白水平